All Videos

Susan Taylor, MD, explained the current state of diversity in clinical trials, what is going well, and opportunities to improve.

Susan Taylor, MD, shared what she wants to know about patients' functionality to treat their atopic dermatitis with hand or foot involvement.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.

Adelaide A. Hebert, MD, FAAD, shares insight on the eczema area and severity index 75 (EASI75) results from the ADORING 1 and ADORING 2 clinical trials for use of tapinarof in AD.

Expert dermatologists review the validated investigator global assessment for AD (vIGA-AD) response in the ADORING 1 and ADORING 2 trials for tapinarof.

An expert in dermatology reviews the case of a 33-year-old male patient suffering from atopic dermatitis for the past 3 years. He breaks down the panel's conversation on the use of non-steroidal topicals and emphasizes how patient assistance programs can ease burden for patients and providers.

Shawn Kwatra, MD, presents a case involving a 73-year-old African American female seeking treatment for her atopic dermatitis. In this segment Dr Kwatra explains the panels thoughts and rationale behind the prescribed treatments, discussing how each option works and its limitations.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the rapid itch reduction results found in the clinical trials for tapinarof in AD, as well as primary end points of the studies.

Expert dermatologists highlight the patient characteristics in the ADORING 1 and ADORING 2 trials, both focusing on tapinarof for the treatment of AD.

Drs Lisa Swanson and Robert J. Casquejo express their optimism for the future of plaque psoriasis management, sharing their vision for expanded treatment approvals in the pediatric population affected by this condition.

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.

George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.

Leon Kircik, MD, emphasizes the combined use of emerging topical treatments with systemic or biologic medications and the impact of the treatment vehicle on penetration. He also discusses the potential for longer use of steroidal options by reducing active product quantities through better penetrating vehicles and highlights the potential heightened efficacy of newer topical treatments and the gaps they may fill in the management of this condition.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review clinical trial data for tapinarof cream, 1% in the treatment of AD.

Expert dermatologists discuss the use of nonsteroidal treatment formulations for the treatment of AD, focusing on a topical treatment, tapinarof cream, 1%.

Lisa Swanson, MD, FAAD and Robert J. Casquejo, PA-C discuss the shifting treatment landscape, shedding light on phosphodiesterase inhibitors-4 (PDE4) and comment on why it holds promise as a therapeutic target for immune-mediated diseases.

Drs Lisa Swanson and Robert J. Casquejo elaborate on their treatment selection approach for plaque psoriasis, underscoring the significance of systemic treatments and their proven efficacy in managing this condition.

An expert in the management of skin conditions highlights the case of a 45-year-old female with severe pruritus, erythematous rash, and lichenification across multiple body areas, worsened by recent work-related stress from a promotion. Dr. Lio offers insights into managing such patients and shares practical tips for a streamlined prescription process.

Peter Lio, MD, presents the case of a 56-year-old female with a history of severe atopic dermatitis and very dry skin. Dr. Lio discusses the significance of accurate disease diagnosis, tools for assessing severity, and the array of treatment options available for this patient. He emphasizes the importance of shared decision-making in managing the condition.

Dr. Elizabeth Kiracofe discusses a case of unstable vitiligo in a 35-year-old male, addressing the impact of an outdoor lifestyle on treatment, the efficacy of topical ruxolitinib, and its utility in difficult-to-repigment areas.

Elizabeth Kiracofe, MD, FAAD presents a case of a 42-year-old woman with facial vitiligo, emphasizing the need for personalized treatment plans. She shares insights on patient follow-up, monitoring practices, and physician preferences in treatment modalities based on the vehicle.

Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.

An expert in dermatology reviews the case of a 10-year-old male with segmental vitiligo, shedding light on the panel's gaps in understanding this complex condition. The conversation explores the treatment challenges and the emotional impact on patients, particularly those of Asian or Indian descent.

Karan Lal DO, MS, FAAD presents the case of a 51-year-old African American male with vitiligo, exploring insurance challenges, treatment options such as topical ruxolitinib, Excimer, and phototherapy, and strategies for setting and managing patient treatment response expectations.

An expert in dermatology presents the case of a 23-year-old male patient presenting with unstable vitiligo. He delves into treatment options available for managing this condition, shedding light on the nuances and optimal scenarios for each therapeutic agent.

James Song, MD, FAAD, presents the case of a 14-year-old male patient seeking vitiligo treatment. He emphasizes the significance of addressing mental health concerns alongside managing the physical symptoms of this condition. He further discusses possible approaches to treat the patient's depigmented patches, particularly considering that this patient was diagnosed with segmental vitiligo.

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options. She also reviews the significance of patient assistance programs in facilitating patient access to and affordability of pharmaceutical therapies.